Barclays’s Ultragenyx Pharmaceutical RARE Stock Holding History

Barclays’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,500	Closed	-$453K	–	5483
2025 Q1	$453K	Buy	+12,500	New	+$520K	﹤0.01%	3593
2024 Q2	–	Sell	-30,000	Closed	-$1.4M	–	5217
2024 Q1	$1.4M	Hold	30,000	–	–	﹤0.01%	2863
2023 Q4	$1.43M	Buy	+30,000	New	+$1.16M	﹤0.01%	3173
2019 Q2	–	Sell	-600	Closed	-$42K	–	7209
2019 Q1	$42K	Hold	600	–	–	﹤0.01%	6003
2018 Q4	$26K	Buy	+600	New	+$32.8K	﹤0.01%	5782
2017 Q4	–	Sell	-100	Closed	-$5K	–	7073
2017 Q3	$5K	Sell	100 -400	-80%	-$23.7K	﹤0.01%	6423
2017 Q2	$31K	Hold	500	–	–	﹤0.01%	5594
2017 Q1	$34K	Buy	+500	New	+$38.1K	﹤0.01%	5551
2015 Q3	–	Sell	-25,000	Closed	-$2.55M	–	7004
2015 Q2	$2.55M	Buy	+25,000	New	+$1.94M	﹤0.01%	2027

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Barclays's RARE Position: Q1 2026 in Review

Barclays reduced its Ultragenyx Pharmaceutical (RARE) stake by 30% in Q1 2026, selling an estimated $2.46M and leaving 249,807 shares worth $5.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1791.

Barclays first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $12.8M in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Barclays held 249,807 shares of Ultragenyx Pharmaceutical worth $5.23M as of Q1 2026.
Barclays sold 109,341 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $2.46M.
Ultragenyx Pharmaceutical made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1791 holding.
Barclays first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
Barclays's Ultragenyx Pharmaceutical position peaked at $12.8M in Q3 2025.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.